{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:13:38Z","timestamp":1758636818422,"version":"3.40.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.therap.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T01:11:26Z","timestamp":1514077886000},"page":"359-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Douleurs musculaires et statines, effet pharmaco ou effet nocebo\u00a0?"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-8573","authenticated-orcid":false,"given":"Charles","family":"Khouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Roustit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.therap.2017.12.004_bib0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosissup.2004.08.026","article-title":"The discovery and development of HMG-CoA reductase inhibitors. 1992","volume":"5","author":"Endo","year":"2004","journal-title":"Atheroscler Suppl"},{"issue":"10059","key":"10.1016\/j.therap.2017.12.004_bib0180","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"25\u00a0Suppl\u00a02","key":"10.1016\/j.therap.2017.12.004_bib0185","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013\u00a0ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/american heart association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.therap.2017.12.004_bib0190","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.therap.2017.12.004_bib0195","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jama.1988.03410030075032","article-title":"A multicenter comparison of lovastatin and cholestyramine therapy for severe primary, hypercholesterolemia. The Lovastatin study group III","volume":"260","author":"The Lovastatin study group III","year":"1988","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.therap.2017.12.004_bib0200","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1172\/JCI110530","article-title":"Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers","volume":"69","author":"Tobert","year":"1982","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.therap.2017.12.004_bib0205","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Auto-antibodies against 3-hydroxy-3-methylglutaryl-coenzyme. A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.therap.2017.12.004_bib0210","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.therap.2017.12.004_bib0215","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.therap.2017.12.004_bib0220","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01\u00a0in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.therap.2017.12.004_bib0225","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2017.12.004_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"du Souich","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.therap.2017.12.004_bib0235","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jacl.2012.06.006","article-title":"Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting","volume":"7","author":"Cziraky","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"9976","key":"10.1016\/j.therap.2017.12.004_bib0240","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000\u00a0participants in 27\u00a0randomised trials","volume":"385","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.therap.2017.12.004_bib0245","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.therap.2017.12.004_bib0250","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.therap.2017.12.004_bib0255","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2011.08.007","article-title":"Statin use and musculoskeletal pain among adults with and without arthritis","volume":"125","author":"Buettner","year":"2012","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.therap.2017.12.004_bib0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.therap.2017.12.004_bib0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.therap.2017.12.004_bib0270","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s40279-017-0681-7","article-title":"Association between statin use and prevalence of exercise-related injuries: a cross-sectional survey of amateur runners in the Netherlands","volume":"47","author":"Bakker","year":"2017","journal-title":"Sports Med"},{"issue":"10088","key":"10.1016\/j.therap.2017.12.004_bib0275","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.therap.2017.12.004_bib0280","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3\u00a0randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.therap.2017.12.004_bib0285","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10\u00a0in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.therap.2017.12.004_bib0290","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138\u00a0current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.therap.2017.12.004_bib0295","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.02.028","article-title":"Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms","volume":"209","author":"Taylor","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.therap.2017.12.004_bib0300","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014\u00a0update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.therap.2017.12.004_bib0305","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.therap.2017.12.004_bib0310","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.therap.2017.12.004_bib0315","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.therap.2017.12.004_bib0320","doi-asserted-by":"crossref","DOI":"10.7326\/M16-0838","article-title":"Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study","author":"Zhang","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.therap.2017.12.004_bib0325","doi-asserted-by":"crossref","first-page":"e005658","DOI":"10.1161\/JAHA.117.005658","article-title":"Utilization of statins beyond the initial period after stroke and 1-year risk of recurrent stroke","volume":"6","author":"Lee","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.therap.2017.12.004_bib0330","doi-asserted-by":"crossref","first-page":"j3030","DOI":"10.1136\/bmj.j3030","article-title":"Is this muscle pain caused by my statin?","author":"Shun-Shin","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.therap.2017.12.004_bib0335","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","article-title":"N-of-1 (single-patient) trials for statin-related myalgia","volume":"160","author":"Joy","year":"2014","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.therap.2017.12.004_bib0170","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717301956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595717301956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:19:04Z","timestamp":1719713944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595717301956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0040595717301956"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2017.12.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Douleurs musculaires et statines, effet pharmaco ou effet nocebo\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}